Sensus Healthcare to Present at the 29th Annual ROTH Conference

BOCA RATON, Fla., March 7, 2017Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), today announced that Joe Sardano, the Company’s chief executive officer, will present a corporate overview at the 29th Annual ROTH Conference on Wednesday, March 15th at 8:30 a.m. Pacific time. The conference will be held at the Ritz-Carlton, Laguna Niguel in Dana Point, Calif. from March 13th through 15th.

To listen to the presentation, investors may visit Sensus Healthcare’s website at www.sensushealthcare.com or by clicking here.

An archived audio of the presentation and accompanying slides will also be available on the company’s website for 90 days.

About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients.

For further information, please visit https://sensus.ericchesbrough.com

Contacts:
Investors
LHA
Kim Sutton Golodetz
(212) 838-3777
[email protected]

To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/sensus-healthcare-to-present-at-the-29th-annual-roth-conference-300419374.html

SOURCE Sensus Healthcare, Inc.

Share this article

The Benefits of SRT

Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:

98.7%+
Non Reoccurrence Rate

No anesthesia, cutting, bleeding, stitching or pain

No downtime or lifestyle restrictions

Super cosmesis, no unsightly scarring

No need for post-treatment reconstructive surgeries

Patient Inquiry

Patient Inquiry

Discover how Sensus Healthcare and the SRT-100TM are removing the physical and emotional pain often associated with skin cancer treatment.
LEARN MORE

Physician Inquiry

Physician Inquiry

Discover how Sensus Healthcare and the SRT-100TM are removing the physical and emotional pain often associated with skin cancer treatment.
LEARN MORE

General Inquiry

General Inquiry

Discover how Sensus Healthcare and the SRT-100TM are removing the physical and emotional pain often associated with skin cancer treatment.
LEARN MORE